In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
Bibliographical notePublisher Copyright:
© 2020, The Author(s).
Copyright 2020 Elsevier B.V., All rights reserved.
- Adenomatous polyposis
- Colon cancer
- Hereditary colorectal cancer
- Lynch syndrome